Data Support Use of Tivozanib in Patients With Advanced Renal Cell Carcinoma

September 9, 2020

Ulka Vaishampayan, MD, discusses the use of tivozanib as treatment of patients with advanced renal cell carcinoma, based on supportive data in the TIVO-3 clinical trial.

Ulka Vaishampayan, MD, professor of oncology at Wayne State University, and chief of the Solid Tumor Program at Barbara Ann Karmanos Cancer Institute, discusses the VEGF tyrosine kinase inhibitor (TKI) tivozanib (Fotivda) as treatment of patients with advanced renal cell carcinoma (RCC), based on supportive data in the TIVO-3 clinical trial.

While this agent is not currently approved in the United States by the FDA, it is approved in Europe where it is used as a single-agent VEGF TKI as treatment of patients with advanced RCC. Based on the results from TIVO-3, however, tivozanib could be a reasonable option for patients with advanced RCC following treatment with both a VEGF TKI and an immune-based regimen.

The TIVO-3 study demonstrated that tivozanib prolonged progression-free survival in this particular patient population, and the agent was also relatively well tolerated, Vaishampayan says. In conclusion, this agent may give patients additional efficacy benefit in the pretreated setting.

<< View more regarding renal cell carcinoma